Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry
Abstract This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. A total of 113 consecutive RA patients who had been treated wit...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cefd54fdc5a84f4fa82fa7059156b450 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cefd54fdc5a84f4fa82fa7059156b450 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cefd54fdc5a84f4fa82fa7059156b4502021-12-02T13:58:10ZPredictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry10.1038/s41598-020-78925-82045-2322https://doaj.org/article/cefd54fdc5a84f4fa82fa7059156b4502020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78925-8https://doaj.org/toc/2045-2322Abstract This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. A total of 113 consecutive RA patients who had been treated with baricitinib were registered in a Japanese multicenter registry and followed for at least 24 weeks. Mean age was 66.1 years, mean RA disease duration was 14.0 years, 71.1% had a history of use of biologics or JAK inhibitors (targeted DMARDs), and 48.3% and 40.0% were receiving concomitant methotrexate and oral prednisone, respectively. Mean DAS28-CRP significantly decreased from 3.55 at baseline to 2.32 at 24 weeks. At 24 weeks, 68.2% and 64.1% of patients achieved low disease activity (LDA) and moderate or good response, respectively. Multivariate logistic regression analysis revealed that no previous targeted DMARD use and lower DAS28-CRP score at baseline were independently associated with achievement of LDA at 24 weeks. While the effectiveness of baricitinib was similar regardless of whether patients had a history of only one or multiple targeted DMARDs use, patients with previous use of non-TNF inhibitors or JAK inhibitors showed lower rates of improvement in DAS28-CRP. The overall retention rate for baricitinib was 86.5% at 24 weeks, as estimated by Kaplan–Meier analysis. The discontinuation rate due to adverse events was 6.5% at 24 weeks. Baricitinib significantly improved RA disease activity in clinical practice. Baricitinib was significantly more effective when used as a first-line targeted DMARDs.Nobunori TakahashiShuji AsaiTomonori KobayakawaAtsushi KanekoTatsuo WatanabeTakefumi KatoTsuyoshi NishiumeHisato IshikawaYutaka YoshiokaYasuhide KanayamaTsuyoshi WatanabeYuji HiranoMasahiro HanabayashiYuichiro YabeYutaka YokotaMochihito SuzukiYasumori SobueKenya TerabeNaoki IshiguroToshihisa KojimaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-10 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Nobunori Takahashi Shuji Asai Tomonori Kobayakawa Atsushi Kaneko Tatsuo Watanabe Takefumi Kato Tsuyoshi Nishiume Hisato Ishikawa Yutaka Yoshioka Yasuhide Kanayama Tsuyoshi Watanabe Yuji Hirano Masahiro Hanabayashi Yuichiro Yabe Yutaka Yokota Mochihito Suzuki Yasumori Sobue Kenya Terabe Naoki Ishiguro Toshihisa Kojima Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| description |
Abstract This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. A total of 113 consecutive RA patients who had been treated with baricitinib were registered in a Japanese multicenter registry and followed for at least 24 weeks. Mean age was 66.1 years, mean RA disease duration was 14.0 years, 71.1% had a history of use of biologics or JAK inhibitors (targeted DMARDs), and 48.3% and 40.0% were receiving concomitant methotrexate and oral prednisone, respectively. Mean DAS28-CRP significantly decreased from 3.55 at baseline to 2.32 at 24 weeks. At 24 weeks, 68.2% and 64.1% of patients achieved low disease activity (LDA) and moderate or good response, respectively. Multivariate logistic regression analysis revealed that no previous targeted DMARD use and lower DAS28-CRP score at baseline were independently associated with achievement of LDA at 24 weeks. While the effectiveness of baricitinib was similar regardless of whether patients had a history of only one or multiple targeted DMARDs use, patients with previous use of non-TNF inhibitors or JAK inhibitors showed lower rates of improvement in DAS28-CRP. The overall retention rate for baricitinib was 86.5% at 24 weeks, as estimated by Kaplan–Meier analysis. The discontinuation rate due to adverse events was 6.5% at 24 weeks. Baricitinib significantly improved RA disease activity in clinical practice. Baricitinib was significantly more effective when used as a first-line targeted DMARDs. |
| format |
article |
| author |
Nobunori Takahashi Shuji Asai Tomonori Kobayakawa Atsushi Kaneko Tatsuo Watanabe Takefumi Kato Tsuyoshi Nishiume Hisato Ishikawa Yutaka Yoshioka Yasuhide Kanayama Tsuyoshi Watanabe Yuji Hirano Masahiro Hanabayashi Yuichiro Yabe Yutaka Yokota Mochihito Suzuki Yasumori Sobue Kenya Terabe Naoki Ishiguro Toshihisa Kojima |
| author_facet |
Nobunori Takahashi Shuji Asai Tomonori Kobayakawa Atsushi Kaneko Tatsuo Watanabe Takefumi Kato Tsuyoshi Nishiume Hisato Ishikawa Yutaka Yoshioka Yasuhide Kanayama Tsuyoshi Watanabe Yuji Hirano Masahiro Hanabayashi Yuichiro Yabe Yutaka Yokota Mochihito Suzuki Yasumori Sobue Kenya Terabe Naoki Ishiguro Toshihisa Kojima |
| author_sort |
Nobunori Takahashi |
| title |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| title_short |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| title_full |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| title_fullStr |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| title_full_unstemmed |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry |
| title_sort |
predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a japanese multicenter registry |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/cefd54fdc5a84f4fa82fa7059156b450 |
| work_keys_str_mv |
AT nobunoritakahashi predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT shujiasai predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT tomonorikobayakawa predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT atsushikaneko predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT tatsuowatanabe predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT takefumikato predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT tsuyoshinishiume predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT hisatoishikawa predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yutakayoshioka predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yasuhidekanayama predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT tsuyoshiwatanabe predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yujihirano predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT masahirohanabayashi predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yuichiroyabe predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yutakayokota predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT mochihitosuzuki predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT yasumorisobue predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT kenyaterabe predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT naokiishiguro predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry AT toshihisakojima predictorsforclinicaleffectivenessofbaricitinibinrheumatoidarthritispatientsinroutineclinicalpracticedatafromajapanesemulticenterregistry |
| _version_ |
1718392287462948864 |